Carbon dioxide levels in neonates: what are safe parameters?

Sie Kei Wong1, M. Chim1, J. Allen1,2, A. Butler1, J. Tyrrell1, T. Hurley1, M. McGovern1, M. Omer1,3, N. Lagan1,2, J. Meehan1,2, E. P. Cummins4 and E. J. Molloy1,2,3,5

There is no consensus on the optimal pCO2 levels in the newborn. We reviewed the effects of hypercapnia and hypocapnia and existing carbon dioxide thresholds in neonates. A systematic review was conducted in accordance with the PRISMA statement and MOOSE guidelines. Two hundred and ninety-nine studies were screened and 37 studies included. Covidence online software was employed to streamline relevant articles. Hypocapnia was associated with predominantly neurological side effects while hypercapnia was linked with neurological, respiratory and gastrointestinal outcomes and Retinopathy of prematurity (ROP). Permissive hypercapnia did not decrease periventricular leukomalacia (PVL), ROP, hydrocephalus or air leaks. As safe pCO2 ranges were not explicitly concluded in the studies chosen, it was indirectly extrapolated with reference to pCO2 levels that were found to increase the risk of neonatal disease. Although PaCO2 ranges were reported from 2.6 to 8.7 kPa (19.5–64.3 mmHg) in both term and preterm infants, there are little data on the safety of these ranges. For permissive hypercapnia, parameters described for bronchopulmonary dysplasia (BPD; PaCO2 6.0–7.3 kPa: 45.0–54.8 mmHg) and congenital diaphragmatic hernia (CDH; PaCO2 ≤ 8.7 kPa: ≤65.3 mmHg) were identified. Contradictory findings on the effectiveness of permissive hypercapnia highlight the need for further data on appropriate CO2 parameters and correlation with outcomes.

Pediatric Research (2022) 91:1049–1056; https://doi.org/10.1038/s41390-021-01473-y

IMPACT:
- There is no consensus on the optimal pCO2 levels in the newborn.
- There is no consensus on the effectiveness of permissive hypercapnia in neonates.
- A safe range of pCO2 of 5–7 kPa was inferred following systematic review.

INTRODUCTION
Carbon dioxide (CO2) is a physiological gas produced as a consequence of aerobic metabolism. Plasma CO2 levels are tightly regulated under physiological conditions to maintain blood pH. CO2 is mainly removed from the body via the lungs and can accumulate in lung pathologies. In humans, normocapnia is defined as a pCO2 of between 4.7 and 6.0 kPa (35.3–45.0 mmHg), with pCO2 reflecting the balance between CO2 production and removal. Consequently, slightly higher pCO2 values are associated with the venous circulation as CO2-enriched blood is returned towards the lungs.1 Importantly, the local microenvironment of cells and tissues can experience pCO2 levels that differ markedly from systemic PaCO2, e.g., in solid tumours.2 This is likely a consequence of local metabolic activity and alterations in local blood supply. Adaptive responses to changes in CO2 can be classified as being acute or chronic. Acute responses to CO2 are generally sensed through brain stem central chemoreceptors that modulate the rate and depth of breathing to try and maintain normocapnic partial pressures of CO2. Chronic responses to CO2 can be elicited on a cellular level through CO2-dependent changes in gene expression, e.g., genes associated with immune signalling.3 The cerebral vasculature is very sensitive to physiological gases. Given the brain's significant demand for oxygen to maintain normal function, several adaptive cerebral vasodilatory mechanisms are elicited to promote and maintain cerebral blood flow under conditions of hypoxia. Elevated CO2 levels, which are frequently associated with hypoxia, also promote an increase in cerebral blood flow through dilation of cerebral arteries and arterioles.4 In contrast, hypocapnia leads to vascular constriction and reduced blood flow. Thus, the cerebral vasculature is highly sensitive to the level of circulating physiological gases with hypocapnia and hypercapnia capable of affecting brain oxygen levels indirectly through modulation of cerebral blood flow.

In healthy neonates, the physiological CO2 range is defined as 4.7–6.0 kPa (35.3–45.0 mmHg).5,6 Given the physiological impact of CO2 levels on cerebral vasculature and the impact of CO2 on immune signalling, it has been suggested that hyper- and hypocapnia can both have detrimental effects for newborn infants. While CO2 monitoring can be undertaken on a continuous basis or intermittently with blood gas measurement, there is currently no consensus on the optimal pCO2 levels in the newborn. Similarly, there is limited evidence as to what is clinical best-practice with respect to managing the care of neonates with moderate hypocapnia and hypercapnia.

1Department of Paediatrics, School of Medicine, Trinity College, The University of Dublin, Trinity Translational Medicine Institute (TTMI) & Trinity Research in Childhood Centre (TRiCC), Dublin, Ireland; 2Childrens Hospital Ireland (CHI) at Tallaght, Tallaght University Hospital, Dublin, Ireland; 3Department of Neonatology, Coombe Women’s and Infant’s University Hospital, Dublin, Ireland; 4School of Medicine and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland and 5Neonatology, CHI at Crumlin, Dublin, Ireland
Correspondence: E J. Molloy (Eleanor.molloy@tcd.ie)

Received: 26 March 2020 Revised: 1 March 2021 Accepted: 2 March 2021
Published online: 6 July 2021
Effects of hypocapnia

Hypocapnia in the neonate may be the result of a disease such as transient tachypnoea of the newborn, or more commonly, induced iatrogenically during mechanical ventilation or extra-corpooreal membrane oxygenation. Permanent brain injury may be caused by cerebral vasoconstriction and low cerebral tolerance of hypoxia, and hypocapnia may worsen ischaemia/reperfusion-induced acute lung injury. There is a correlation between the degree and duration of hypocapnia and the incidence and severity of these lesions. In both term and preterm neonates, hypocapnia can therefore be a risk factor for central nervous system damage which may manifest as cerebral palsy (CP), cognitive or developmental disabilities, intraventricular haemorrhage (IVH), periventricular white matter injury and auditory impairment.

Effects of hypercapnia

Autoregulation of cerebral blood flow and subsequent cerebral oxygenation is undermined when pCO₂ levels increase. Severe hypercapnia is of concern due to the risk of cerebral oedema and vasodilation, particularly in relation to infants with neonatal encephalopathy (NE). High PaCO₂ predisposes preterm infants to IVH, and maximum pCO₂ seems to be an important factor for severe IVH in the first three postnatal days. Severe hypercapnia alters consciousness and mental state, induces spasms and suppresses cortical activity, which is associated with impaired outcome in preterm infants. There is also a significant association between hypercapnia in low weight infants and bronchopulmonary dysplasia (BPD) as compared to normocapnic controls.

A greater prevalence of necrotising enterocolitis (NEC) was observed in premature neonates with a higher pCO₂ target (7.3–10.0 kPa = 54.8–75.0 mmHg) as compared to the normal target group. Neonatal survival rate was associated with the level of PaCO₂ in patients with congenital diaphragmatic hernia (CDH). Infants with CDH that remained hypercapnic post-resuscitation (9.6 ± 2.5 kPa = 72.0 ± 18.8 mmHg) had a worse prognosis as compared to those who were normocapnic. However, it is important to note that this observation may be explained by the severity of lung hypoplasia, with more severe hypoplasia manifesting as persistent hypercapnia.

The need for mechanical ventilation in the neonatal period has been associated with lung injury and long-term respiratory morbidity, such as BPD. There is also a higher risk of premature brain injury such as periventricular leukomalacia (PVL) and IVH associated with its use. The duration and intensity of ventilation has been implicated in the pathogenesis of neonatal lung injury with large tidal volumes and resultant volutrauma being especially damaging to the immature lung. Permissive hypercapnia is a ventilatory strategy that permits relatively high levels of CO₂ in ventilated neonates, thereby allowing lower tidal volumes to be used in patients who are mechanically ventilated. This less aggressive approach to ventilation reduces the risk of volutrauma in ventilated neonates and may improve respiratory outcomes and survival rates. Effective CO₂ elimination can occur at lower tidal volumes and peak inspiratory pressures as increased PaCO₂ achieved using permissive hypercapnia increases CO₂ elimination for the same minute ventilation (from the equation \( k \times V_{CO_2} = PaCO_2 \times Va \), with Va representing alveolar ventilation). Hypercapnic acidosis also improves ventilation–perfusion mismatch and allows greater unloading of O₂ at the tissues (Bohr effect). In addition, there is also an increased respiratory drive to reduce apnoea and increased cardiac output. Thus, it has been widely employed in the ventilation of preterm infants. We aimed to determine safe pCO₂ levels in neonates with reference to the potential side effects of hypercapnia and hypocapnia identified within this population.

METHODS

Literature search

The methodology of this systematic review was designed and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and guidelines from the Meta-analysis of Observational Studies in Epidemiology (MOOSE). A literature search was done on Pubmed, Embase and Scopus and the terms undertaken were: “neonates” AND (“hypocapnia” OR “hypercapnia”). Additional studies identified during a manual search were also included.

Inclusion and exclusion criteria

Studies that satisfied the following criteria were included into our literature review: (1) full text available in English, (2) human subjects and (3) peer-reviewed journals. Exclusion criteria were established to eliminate studies beyond the scope of the review: editorials; letters and case reports; duplicate publications; and use of animal models. The publication years were not restricted due to a limitation in the number of studies available.

Quality assessment and data extraction

In the first phase of selection, the titles and abstracts were reviewed by two independent reviewers to determine their relevance. Disagreements were either resolved by a third reviewer or settled by consensus. The second phase of selection involved full text screening where an independent reviewer determined their eligibility. Covidence online software was employed in both phases of screening to streamline the relevant articles. Data extracted includes (1) side effects of hypercapnia, hypocapnia and permissive hypercapnia, (2) pCO₂, PaCO₂ or PcCO₂ levels and (3) population characteristics. Analysis was subsequently performed, and results were tabulated according to preterm and term neonates (Tables 1 and 2). As safe pCO₂ ranges were not explicitly concluded in the studies chosen, it was indirectly extrapolated with reference to pCO₂ levels that were found to increase the risk of neonatal disease. The data were then categorised based into pre-term and term neonates and term infants. The quality of the studies was assessed using the hierarchy of evidence.

RESULTS

Two hundred and ninety-nine studies were identified via database searching and 18 additional studies were identified through manual searching. There were 261 papers after duplicates were removed. Seventy-seven full-text articles remained after the first round of screening and 37 studies were included in this review (Fig. 1).

Preterm infants

Hypocapnia. Brown et al. reviewed the range of permissive hypercapnia used in clinical practice and determined the relationship between PaCO₂ and pH during the first three days of life and negative health outcomes. Their subjects were 147 premature neonates who were less than 32 weeks gestational age. Preterm infants of less than 29 weeks gestational age had a higher risk of severe IVH and PVL if their PaCO₂ fell below 4.0 kPa (30.0 mmHg) within the first two days of life. Similarly, if the same group of infants had at least 3 PaCO₂ values less than 4.0 kPa (30.0 mmHg) within the first day of life they were at increased risk of BPD (p = 0.036).

Liu et al. prospectively found a significantly higher incidence of PVL in premature newborns with hypocapnia (PaCO₂ ≤ 4.67 kPa = 35.0 mmHg) as compared to the preterm control group, suggesting that hypocapnia is an important high-risk factor for PVL. A prospective study by Collins et al. which involved 1105 infants with birth weight between 500 and 2000 g found that the unadjusted univariate rates of disabling CP within ventilated infants by quintile of cumulative hypocapnia exposure has a
| Pathology | Citation | Study type | Safe range | Comments |
|-----------|----------|------------|------------|----------|
| BPD       | Subramanian et al. \textsuperscript{a}, \textit{n} = 425 | Observational cohort multicentre study (Level 4) | $\text{pCO}_2 < 6.67 \text{ kPa}$ ($<50.0 \text{ mmHg}$) | May reduce the risk of BPD in low and extremely low birth weight infants |
|           | Mariani et al. \textsuperscript{b}, \textit{n} = 49 | RCT (Level 3) | $\text{PaCO}_2 6.0–7.3 \text{ kPa}$ ($45.0–54.8 \text{ mmHg}$) | May be a viable alternative to normocapnia in extremely preterm neonates treated with surfactant |
|           | Thome et al \textsuperscript{c} (2018), \textit{n} = 359 | Exploratory analysis of a RCT (Level 3) | $\text{pCO}_2 < 7.33 \text{ kPa}$ ($<55.0 \text{ mmHg}$) | Hypercapnia significantly increases mortality and incidence of BPD of extremely low birth weight infants |
|           | Carlo et al. \textsuperscript{d} (2002), \textit{n} = 220 | RCT (Level 3) | $\text{PaCO}_2 < 6.8 \text{ kPa}$ ($<51.0 \text{ mmHg}$) | Does not decrease mortality and incidence of BPD in extremely low weight infants, however, use of mechanical ventilation at 36 weeks is reduced |
| IVH       | Ambalavanan N et al. \textsuperscript{e} \textit{n} = 1316 | Secondary analysis of a RCT (Level 3) | $\text{PaCO}_2 6.0–7.3 \text{ kPa}$ ($45–55 \text{ mmHg}$) | Higher maximum $\text{PaCO}_2$ is associated with higher risk of IVH and mortality in extremely low birth weight infants independently |
|           | Zayek et al. \textsuperscript{f} (2014), \textit{n} = 580 | Retrospective cohort study (Level 4) | $\text{pCO}_2 < 6.0 \text{ kPa}$ ($<45.0 \text{ mmHg}$) | May lower the risk of IVH in extremely low birth weight infants |
|           | Vela-Huerta et al. \textsuperscript{g} (2009), \textit{n} = 83 | Retrospective case control study (Level 5) | $\text{PaCO}_2 < 7.3 \text{ kPa}$ ($<45.0 \text{ mmHg}$) | May lower the risk of severe IVH in extremely low birth weight infants |
|           | Köksal et al. \textsuperscript{h} (2002), \textit{n} = 120 | Prospective cohort study (Level 4) | $\text{PaCO}_2 < 8.0 \text{ kPa}$ ($<60.0 \text{ mmHg}$) | May decrease the risk of IVH in very low and extremely low birth weight premature infants |
|           | Waitz et al. \textsuperscript{i}, \textit{n} = 279 | Retrospective cohort study (Level 4) | $\text{PaCO}_2 5.3–7.7 \text{ kPa}$ ($39.8–57.8 \text{ mmHg}$) | Moderate permissive hypercapnia ($5.3–7.7 \text{ kPa}$ or $39.8–57.8 \text{ mmHg}$) is possible in extremely preterm neonates with GM-IVH Avoid $\text{PaCO}_2$ levels >7.7 kPa (or >57.8 mmHg) as increases risk IVH |
|           | Fabres et al. \textsuperscript{j}, \textit{n} = 849 | Retrospective cohort study (Level 4) | $\text{PaCO}_2 5.2–8.0 \text{ kPa}$ ($39.0–60.0 \text{ mmHg}$) | The suggested optimum $\text{PaCO}_2$ range in very low and extremely low birth weight and extremely preterm babies. Extreme $\text{PaCO}_2$ values ($>60 \text{ mmHg}$) should also be avoided in this group |
| PVL       | Liu et al. \textsuperscript{k}, \textit{n} = 921 | Prospective cohort study (Level 4) | $\text{PaCO}_2 > 4.67 \text{ kPa}$ ($>35.0 \text{ mmHg}$) | Significant increase in incidence of PVL in premature infants that are hypocapnic ($\text{PaCO}_2 \leq 4.67 \text{ kPa}$ or $\leq35.0 \text{ mmHg}$) |
| Neurodev & CP | Thome et al. \textsuperscript{l} (2017), \textit{n} = 359 | RCT (Level 3) | $\text{PaCO}_2 < 7.3 \text{ kPa}$ ($<54.8 \text{ mmHg}$) | May decrease the risk of mortality and neurodevelopmental impairment |
|           | Brown et al. \textsuperscript{m}, \textit{n} = 147 | Secondary analysis RCT (Level 3) | $\text{PaCO}_2 6.0–6.7 \text{ kPa}$ ($45.0–50.3 \text{ mmHg}$) | May be safe neurologically. $\text{PaCO}_2$ should be <7.0 kPa (or 52.5 mmHg) as $\text{PaCO}_2$ above 7.0 kPa (or 52.5 mmHg) is associated with severe IVH and death |
|           | Collins et al. \textsuperscript{n} (2001), \textit{n} = 657 | Prospective cohort study (Level 4) | $\text{PaCO}_2 > 4.7 \text{ kPa}$ ($>35.3 \text{ mmHg}$) | Recommended avoiding $\text{PaCO}_2$ levels <4.7 kPa (or <35.3 mmHg) during mechanical ventilation in very low birth weight infants |

\textsuperscript{1} kPa = 7.5 mmHg = 7.5 torr = 10.2 mm H$_2$O; BPD bronchopulmonary dysplasia, IVH intraventricular haemorrhage, GM-IVH germinal matrix-intraventricular haemorrhage, PVL periventricular leukomalacia, CP cerebral palsy.
Hypercapnia. A randomised controlled trial carried out by Carlo et al among 220 extremely low birth weight infants found that permissive hypercapnia (PaCO$_2$ > 6.93 kPa = 52.0 mmHg) did not significantly decrease mortality or incidence of BPD ($p = 0.43$). However, the use of mechanical ventilation at 36 weeks is statistically significant and increased the risk of BPD or death ($p < 0.0002$). Thorne et al. found that mortality and incidence of moderate-to-severe BPD were significantly raised in hypercapnic extremely low birth weight premature newborns ($p < 0.01$) in a multicentre study. In concordance with these results, a retrospective cohort study of 268 extremely premature infants of very low and extremely low birth weight observed higher rates of severe IVH in infants with larger PaCO$_2$ fluctuations ($p = 0.02$).

Ambalavanan et al. in the secondary analysis of the SUPPORT trial (a large multicentre trial) found that higher peak PaCO$_2$ correlated with an increased risk of severe IVH/death ($p = 0.029$) and neurological impairment/death even at lower ranges of hypercapnia. Higher maximum PaCO$_2$ was an independent risk factor for severe IVH/death even after statistical adjustment for illness severity.

A retrospective cohort study by Zayek et al. investigated the role of mild to moderate hypercapnia (6.0–8.0 kPa = 45.0–60.0 mmHg) and acidemia in the occurrence of severe IVH in 580 extremely low birth weight infants within the first 48 h of life. They found that higher PaCO$_2$ (PaCO$_2$ > 8.0 kPa = 60.0 mmHg) was significantly associated with increased rates of severe IVH as compared to normocapnic infants.

Vela-Huerta et al. conducted a single centre retrospective case–control study on 28 cases of extremely low birth weight preterm infants with grade III or IV IVH and 55 controls and found that PaCO$_2$ > 7.3 kPa (>54.8 mmHg) was only associated with grade IV IVH. Köksal et al. found hypercapnia (pCO$_2$ > 8.0 kPa or >60.0 mmHg) to be a risk factor for IVH ($p < 0.0001$) in 120 premature infants with very low and extremely low birth weight. In a retrospective study, Fabres et al. established that extreme PaCO$_2$ levels and the magnitude of PaCO$_2$ fluctuation were good indicators of severe IVH in very low and extremely low birth weight preterm babies. They have also identified that maximal PaCO$_2$ > 8.0 kPa (>60.0 mmHg) and time-weighted PaCO$_2$ > 7.0 kPa (>52.5 mmHg) are associated with severe IVH. The optimal range of PaCO$_2$ derived by the team was 5.2–8.0 kPa (39.0–60.0 mmHg) and at that range, there was only a 3% incidence of severe IVH.

Waitz et al. explored the risk factors of IVH in extremely preterm neonates. Higher maximal PaCO$_2$ was a risk factor for IVH.
(\(p = 0.001\)) and the risk increased by a factor of 1.04 for every 0.13 kPa (0.98 mmHg).[^14] The same study further quantified that moderate permissive hypercapnia (7.3–8.7 kPa = 54.8–65.2 mmHg) was not associated with a higher incidence of severe IVH when compared to the normocapnic group (5.3–7.7 kPa = 39.8–57.8 mmHg). Ali et al.[^37] stated that there was a significant independent association between hypercapnia and the development of Retinopathy of prematurity (ROP), making hypercapnia a significant variable of development of ROP.

Neonatal encephalopathy

Hypocapnia. Lopez Laporte et al. studied 198 newborns exposed to asphyxia and found a possible association between hypocapnia and the severity of the brain injury. They also highlighted that "asphyxiated" newborns treated with ventilation and hypothermia have higher incidences of brain injury.[^13]

Moderate hypocapnia (2.6–4.7 kPa = 19.5–35.3 mmHg) was not found to be a significant risk factor of severe disability and death in NE by Nadeem et al.[^38] or Hansen et al.[^39] Hansen et al. found no effect of moderate, severe hypocapnia or time-weighted cumulative hypocapnia on neurodevelopmental outcomes. However, Hansen and co-workers suggested that neonates with NE who are treated with therapeutic hypothermia should not be over-ventilated to prevent hypocapnia and its adverse effects.[^38,39]

Pappas et al. found that minimum pCO\(_2\) defined as isolated severe hypocarbia, cumulative pCO\(_2\) < 4.7 kPa (35.3 mmHg), and larger pCO\(_2\) fluctuations in the first 16 h of life were associated with disability and death at 18–22 months in neonates that have NE. The greater the cumulative exposure, the worse the outcome and minimum pCO\(_2\) was the only significant predictor of negative outcome.[^40]

Consistent with the findings by Pappas et al., Linggapan et al. suggested that probability of an unfavourable outcome increases as pCO\(_2\) values decrease. In newborns with severe NE, hypocapnia (pCO\(_2\) between 2.7 and 5.3 kPa = 20.3–39.8 mmHg) was associated with a higher probability of unfavourable outcome as compared to those with moderate NE.[^4]

Hypercapnia. A retrospective cohort study by Lopez Laporte et al. found that neither the magnitude of CO\(_2\) fluctuations nor hypercapnia were significant risk factors for brain injury in NE. Hypercapnia was not a significant risk factor for severe disability and death in infants with NE. A similar relationship was also illustrated in a study by Pappas et al., which reported that maximum pCO\(_2\) and cumulative exposure to hypercapnia were not significant predictors of disability or death. Although NE infants with cumulative pCO\(_2\) above the 50th percentile were more likely to have seizures and needed more time to achieve spontaneous respiration, only the time to spontaneous respiration of more than 10 min had a significant association with adverse outcomes.[^41] Hansen et al. retrospectively studied 23 neonates with moderate to severe NE treated with 72 h of hypothermia and it was found that those from the group with adverse neurodevelopmental outcomes had greater Paco\(_2\) variability than those from the group with favourable neurodevelopmental outcomes. The hypoxic-ischaemic encephalopathy therapy optimization in neonates for better neuroprotection with inhaled CO\(_2\) (HENRIC) study, which involved 10 term infants, recently demonstrated that inhaled 5% CO\(_2\) was feasible and safe for correcting hypocarbia in NE.[^41]

Congenital diaphragmatic hernia. CDH is associated with pulmonary hypoplasia and respiratory distress at birth and infants with CDH frequently require mechanical ventilation following delivery. Abbas et al. found that neonates with CDH who remained hypercapnic (PaCO\(_2\) > 9.6 kPa > 72.0 mmHg) had poorer

---

[^14]: Bégin et al.
[^37]: Ali et al.
[^38]: Nadeem et al.
[^39]: Hansen et al.
[^40]: Pappas et al.
[^4]: Verhamme et al.
[^41]: Hansen et al.
The incidence of permissive hypercapnia in neonates, which is defined as maintaining a PaCO2 above the lower limit of normal, is controversial. Some studies have shown that this approach may be beneficial in reducing the risk of BPD and improving neurodevelopmental outcomes. However, other studies have found no or even adverse effects with permissive hypercapnia.

**Permissive Hypercapnia**

Permissive hypercapnia is a strategy that involves maintaining a PaCO2 within a range of 4.6 to 6.5 kPa (35.3 to 49.0 mmHg) to allow for spontaneous breathing and to minimize the risk of BPD and airway injuries. This approach is based on the concept that a lower PaCO2 may exacerbate cerebral hypoxia and lead to increased cerebral blood flow, which can worsen neurological outcomes in preterm infants.

**Hypercapnia**

Hypercapnia is not always detrimental, and in some cases, it can help prevent or reduce the risk of BPD. The optimal level of PaCO2 is not yet established, and ongoing research is needed to determine the best practice. However, in general, permissive hypercapnia is considered a safe and effective strategy for managing respiratory distress in neonates.
have anti-inflammatory effects and indeed was found to be protective in a recent clinical trial of “therapeutic hypercapnia” in single lung lobectomy patients. The molecular mechanisms underlying CO₂-dependent suppression of immune signalling are not fully elucidated but likely involve suppression of pro-inflammatory signalling cascades. The master-regulator of immune and inflammatory signalling, nuclear factor κB (NFκB), has been implicated in both hypercapnia and hypercapnic acidosis. Cummins et al. have reported CO₂-dependent modulation of the NFκB pathway on multiple levels including protein localisation, transcriptional activation and protein–protein interactions. The concept of NFκB sensitivity to CO₂ levels is additionally supported by several studies from the Laffey lab and others. While CO₂-dependent modulation of NFκB signalling is important in several cell types it is likely that other factors are also involved alone or in combination with NFκB, including HSF-1, FOXO3a and CREB. Thus, CO₂ represents a potentially modifiable factor with the potential to suppress damaging inflammatory signalling in the lung. However, this benefit does not extend to neonates who have sustained ventilator-associated injuries as hypercapnic acidosis impedes plasma membrane repair.

This review was limited by the research design utilised by the studies included. Some studies comprised small cohorts with multiple clinical morbidities making it statistically underpowered and thus cannot make associations or establish causal relationships. The retrospective nature of some studies also affects the credibility of the information presented. Different ventilation settings and different sources of blood gas samples (e.g. arterial, capillary and venous) across the cohort can affect the accuracy of the results obtained. For example, capillary and venous samples may artificially increase pCO₂ values and overestimate the effects hypocapnia and hypercapnia have on neonates. Different CO₂ measurement methods (e.g. blood gas, capnography) also contribute to variation in the results obtained. Lastly, fixed interval monitoring rather than continuous monitoring may overlook important CO₂ trends.

Based on the literature review performed, it appears that pCO₂ levels of approximately 5–7 kPa (37.5–52.5 mmHg) may be safe for neonates requiring ventilatory support. Intervention to therapeutically alter carbon dioxide has been suggested in the recent HENRIC study which demonstrated the use of CO₂ insufflation to prevent hypocarbia in NE. While the research for safe O₂ ranges in preterm and term infants is well underway, the same advance—need for rigorous evidence to establish the role of permissive hypercapnia. Until safe ranges have been defined, this ventilation strategy should be used with caution.

Acknowledgements

E.J.M. is funded by the Health Research Board, Ireland; E.P.C. is funded by Science Foundation Ireland (15/CDA/3490).

Author Contributions

S.K.W. contributed to acquisition, analysis and interpretation of data; drafting and revising the article; and approving the final version. M.C., A.B., J.T. and M.O. contributed to design; acquisition, analysis and interpretation of data; drafting and revising the article; and approving the final version. J.A. and N.L. contributed to design; analysis and interpretation of data; revising the article; and approving the final version. T.H., M.M.G. and E.P.C. contributed to analysis and interpretation of data; revising the article; and approving the final version. J.M. contributed to design; acquisition, analysis and interpretation of data; revising the article; and approving the final version. E.J.M. contributed to conception and design; acquisition, analysis and interpretation of data; drafting and revising the article; and approving the final version.

Funding

Open Access funding provided by the IReL Consortium.

Additional Information

Competing Interests: The authors declare no competing interests.

Consent: Patient consent was not required for this review of the literature.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Cummins, E. P., Strowitzki, M. J. & Taylor, C. T. Mechanisms and consequences of oxygen and carbon dioxide sensing in mammals. *Physiol. Rev.* 100, 463–488 (2020).
2. Kikuchi, R. et al. Hypercapnic tumor microenvironment confers chemoresistance to lung cancer cells by reprogramming mitochondrial metabolism in vitro. *Free Radic. Biol. Med.* 134, 200–214 (2019).
3. Cummins, E. P. & Keogh, T. Respiratory gases and the regulation of transcription. *Exp. Physiol.* 101, 986–1002 (2016).
4. Lingappa, K., Kaiser, J. R., Srinivasan, C. & Gumn, A. J. Relationship between PCO₂ and unfavorable outcome in infants with moderate-to-severe hypoxic ischemic encephalopathy. *Pediatr. Res.* 80, 204–208 (2016).
5. Liu, J., Li, J., Qin, G. L., Chen, Y. H. & Wang, Q. Periventricular leukomalacia in premature infants in mainland China. *Am. J. Perinatol.* 25, 535–540 (2008).
6. Zhou, W. & Liu, W. Hypercapnia and hypocapnia in neonates. *World J. Pediatr.* 4, 192–196 (2008).
7. Thome, U. H. & Ambalavanan, N. Permissive hypercapnia to decrease lung injury in ventilated preterm neonates. *Semin. Fetal Neonatal Med.* 14, 21–27 (2009).
8. Vanderhaegen, J. et al. The effect of changes in pCO₂ on the fractional tissue oxygen extraction—as measured by near-infrared spectroscopy—in neonates during the first days of life. *Eur. J. Paediatr. Neurol.* 13, 128–134 (2009).
9. Brown, M. K. et al. Incidence of hypocapnia, hypercapnia, and acidosis and the associated risk of adverse events in preterm neonates. *Respir. Care* 63, 943–949 (2018).
10. Fabres, J., Carlo, W. A., Phillips, V., Howard, G. & Ambalavanan, N. Both extremes of arterial carbon dioxide pressure and the magnitude of fluctuations in arterial carbon dioxide pressure are associated with severe intraventricular hemorrhage in preterm infants. *Pediatrics* 119, 299–305 (2007).
11. Kaiser, J. R., Gauss, C. H., Pont, M. M. & Williams, D. K. Hypercapnia during the first 3 days of life is associated with severe intraventricular hemorrhage in very low birth weight infants. *J. Perinatol.* 26, 279–285 (2006).
12. Thome, U. H. & Carlo, W. A. Permissive hypercapnia. *Semin. Neonatol.* 7, 409–419 (2002).
13. Lopez Laporte, M. A. et al. Association between hypocapnia and ventilation during the first days of life and brain injury in asphyxiated newborns treated with hypothermia. *J. Matern. Fetal Neonatal Med.* 32, 1312–1320 (2019).
14. Waltz, M. et al. Risk factors associated with intraventricular hemorrhage in preterm infants with c<–28 weeks gestational age. *Klin. Pediatr.* 228, 245–250 (2016).
15. Weeke, L. C. et al. Severe hypercapnia causes reversible depression of aEEG background activity in neonates: an observational study. *Arch. Dis. Child Fetal Neonatal Ed.* 102, F383–F388 (2017).
16. Subramanian, S., El-Mohandes, A., Dhanireddy, R. & Koch, M. A. Association of bronchopulmonary dysplasia and hypercapnia in ventilated infants with birth weights of 500–1499 g. *Matern Child Health J.* 15, 517–526 (2011).
17. Thome, U. H. et al. Permissive hypercapnia in extremely low birthweight infants (PEHELBI): a randomised controlled multicentre trial. *Lancet Respir. Med.* 3, 534–543 (2015).
18. Abbas, P. I. et al. Persistent hypercapnia after resuscitation is associated with increased mortality in congenital diaphragmatic hernia patients. *J. Pediatr. Surg.* 50, 739–743 (2015).
19. Ramanathan, R. & Sardesai, S. Lung protective ventilatory strategies in very low birth weight infants. *J. Perinatol.* 28, 541–546 (2008).
20. Avery, M. E. et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. *Pediatrics* 79, 26–30 (1987).
21. Ambalavanan, N. & Carlo, W. A. Hypocapnia and hypercapnia in respiratory management of newborn infants. *Clin. Perinatol.* 28, 517–531 (2001).
22. Mariani, G., Cifuentes, J. & Carlo, W. A. Randomized trial of permissive hypercapnia in preterm infants. *Pediatrics* 104, 1082–1088 (1999).
23. Ryu, J., Haddad, G. & Carlo, W. A. Clinical effectiveness and safety of permissive hypercapnia. *Clin. Perinatol.* 39, 603–612 (2012).

Carbon dioxide levels in neonates: what are safe parameters? SK Wong et al.
Carbon dioxide levels in neonates: what are safe parameters?

SK Wong et al.

24. Jankov, R. P., & Tanswell, A. K. Hypercapnia and the neonate. Acta Paediatr. 97, 1502–1509 (2008).
25. Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162, 777–784 (2015).
26. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology, a proposal for reporting. JAMA 283, 2008–2012 (2000).
27. Veritas Health Innovation M. Australia. Covidence systematic review software. www.covidence.org (2019).
28. Winona State University Darrell W. Krueger Library, Minnesota. Evidence Based Practice Toolkit. https://libguides.winona.edu/c.php?g=11614&p=61584#:~:text=Levels%20of%20evidence%20(sometimes%20called,or%20strength)%20of%20recommendation%22 (2020).
29. Collins, M. P., Lorenz, J. M., Jetton, J. R. & Paneth, N. Hypocapnia and other ventilation-related risk factors for cerebral palsy in low birth weight infants. Pediatr. Res. 50, 712–719 (2001).
30. Carlo, W. A. et al. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J. Pediatr. 141, 370–374 (2002).
31. Ambalavanar, N. et al. PaCO2 in surfactant, positive pressure, and oxygenation randomized trial (SUPPORT). Arch. Dis. Child Fetal Neonatal Ed. 100, F145–F149 (2015).
32. Thome, U. H. et al. Influence of PCO2 control on clinical and neurodevelopmental outcomes of extremely low birth weight infants. Neonatology 113, 221–230 (2018).
33. Alakaany, D., Natarajan, G., Gupta, D., Zidan, M. & Chawla, S. Severe intraventricular hemorrhage in extremely premature infants: are high carbon dioxide pressure or fluctuations the culprit? Am. J. Perinatol. 32, 839–844 (2015).
34. Zayek, M. M. et al. Acidemia versus hypercapnia and risk for severe intraventricular hemorrhage. Am. J. Perinatol. 31, 345–352 (2014).
35. Vela-Huerta, M. M., Amador-Licona, M., Medina-Ovando, N. & Aldana-Valenzuela, C. Factors associated with early severe intraventricular haemorrhage in very low birth weight infants. Neuropediatrics 40, 224–227 (2009).
36. Koksal, N., Baytan, B., Bayram, Y. & Nacarkucuk, E. Risk factors for intraventricular haemorrhage in very low birth weight infants. Neuropediatrics 40, 224–227 (2009).
37. Ali, A. A., Gornaa, N. A. S., Awadeen, A. R., Al-Hayouti, H. H. & Hegazy, A. I. Retrospective cohort study shows that the risks for retinopathy of prematurity included birth age and weight, medical conditions and treatment. Acta Paediatr. 106, 1919–1927 (2017).
38. Nadeem, M., Murray, D., Boylan, G., Dempsey, E. M. & Ryan, C. A. Blood carbon dioxide levels and adverse outcome in neonatal hypoxic-ischemic encephalopathy. Am. J. Perinatol. 27, 361–365 (2010).
39. Hansen, G., Al Shafouri, N., Narvey, M., Vallance, J. K. & Srinivasan, G. High blood carbon dioxide variability and adverse outcomes in neonatal hypoxic ischemic encephalopathy. J. Matern Fetal Neonatal Med. 29, 680–683 (2016).
40. Pappas, A. et al. Hypocarbia and adverse outcome in neonatal hypoxic-ischemic encephalopathy. J. Pediatr. 158, 752–8 e1 (2011).
41. Szakmar, E. et al. Neonatal encephalopathy therapy optimization for better neuroprotection with inhalation of CO2: the HENRIC feasibility and safety trial. Pediatr. Res. 87, 1025–1032 (2019).
42. Bujan, K. et al. Survival of outborns with congenital diaphragmatic hema: the role of protective ventilation, early presentation and transport distance: a retrospective cohort study. BMC Pediatr. 15, 155 (2015).
43. Ma, J. & Ye, H. Effects of permissive hypercapnia on pulmonary and neurodevelopmental sequelae in extremely low birth weight infants: a meta-analysis. Springerplus 5, 764 (2016).
44. Thome, U. H. et al. Outcome of extremely preterm infants randomized at birth to different PaCO2 targets during the first seven days of life. Biol. Neonate. 90, 218–225 (2006).
45. Molloy, E. J. & Cummins, E. P. Carbon dioxide as a drug in neonatology. Pediatr. Res. https://doi.org/10.1016/s1139-0210(15)-y (2020).
46. Hagen, E. W., Sadek-Badawi, M., Carlton, D. P. & Palta, M. Permissive hypercapnia and risk for brain injury and developmental impairment. Pediatrics 123, 583–589 (2008).
47. Resch, B. et al. Episodes of hypocarbia and early-onset sepsis are risk factors for cystic periventricular leukomalacia in the preterm infant. Early Hum. Dev. 88, 27–31 (2012).
48. Santosh, K. K. Apnea in neonates—concepts and controversies. Progressing Asp. Pediatrics Neonatol. 2, 130–134 (2019).
49. Thome, U. H. et al. Neurodevelopmental outcomes of extremely low birthweight infants randomized to different PCO2 targets: the PHELBI follow-up study. Arch. Dis. Child Fetal Neonatal Ed. 102, F376–F382 (2017).
50. Skouteli, H. N. et al. Arterial blood gas derangements associated with death and intracranial hemorrhage in premature babies. J. Perinatol. 8, 336–341 (1988).
51. Ahmadz, Z., Boseıñk-Hermansson, A., Franklin, K. A., Midgren, B. & Ekstrom, M. P. Hypo- and hypercapnia predict mortality in oxygen-dependent chronic obstructive pulmonary disease: a population-based prospective study. Respir. Res. 15, 30 (2014).
52. Nín, N. et al. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. Intensive Care Med. 43, 200–208 (2017).
53. Lasema, E. et al. Hypocapnia and hypercapnia are predictors for ICU admission and mortality in hospitalized patients with community-acquired pneumonia. Chest 142, 1193–1199 (2012).
54. Gao, W., Liu, D. D., Li, D. & Cui, G. X. Effect of therapeutic hypercapnia on inflammatory responses to one-lung ventilation in lobectomy patients. Anesthesiology 122, 1235–1252 (2015).
55. Cummins, E. P. et al. NF-kappaB links CO2 sensing to innate immunity and inflammation in mammalian cells. J. Immunol. 185, 4439–4445 (2010).
56. Keogh, C. E. et al. Carbon dioxide-dependent regulation of NF-kappaB family members ReIß and p100 gives molecular insight into CO2-dependent immune regulation. J. Biol. Chem. 292, 11561–11571 (2017).
57. Contreras, M. et al. Hypercapnic acidosis attenuates ventilation-induced lung injury by a nuclear factor-kappaB-dependent mechanism. Crit. Care Med. 40, 2622–2630 (2012).
58. O’Toole, D. et al. Hypercapnic acidosis attenuates pulmonary epithelial wound repair by an NF-kappaB dependent mechanism. Thoxa 64, 976–982 (2009).
59. Taylor, C. T. & Cummins, E. P. Regulation of gene expression by carbon dioxide. J. Physiol. 589, 797–803 (2011).
60. Lu, Z. et al. A role for heat shock factor 1 in hypercapnia-induced inhibition of inflammatory cytokine expression. FASEB J. 32, 3614–3622 (2018).
61. Jaitovich, A. et al. High CO2 levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific Ringer finger protein 1 (MurF1). J. Biol. Chem. 290, 9183–9194 (2015).
62. Townsend, P. D. et al. Stimulation of mammalian G-protein-responsive adenylyl cyclases by carbon dioxide. J. Biol. Chem. 284, 784–791 (2009).
63. Doerr, C. H. et al. Hypercapnic acidosis impairs plasma membrane wound sealing in ventilator-injured lungs. Am. J. Respir. Crit. Care Med. 171, 1271–1277 (2005).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021